Edgewise Therapeutics joined PPMD for a community webinar on October 18, 2023 to discuss the company’s investigational compound, EDG-5506. Joanne M. Donovan, M.D., Ph.D., Chief Medical Officer at Edgewise, and Alan Russell, Ph.D., Edgewise’s Co-Founder and Chief Scientific Officer, provided an overview of results from the ongoing open-label ARCH study in adults with Becker muscular dystrophy and shared information about Edgewise’s currently enrolling trial, GRAND CANYON, a phase 2 trial for adults living with Becker.